CoChat

miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosis

Open access
Loffreda, Alessia, Nizzardo, Monica, Arosio, Alessandro, Ruepp, Marc-David, Calogero, Raffaele A., Volinia, Stefano, Galasso, Marco, Bendotti, Caterina, Ferrarese, Carlo, Lunetta, Christian, Rizzuti, Mafalda, Ronchi, Antonella E., Mühlemann, Oliver, Tremolizzo, Lucio, Corti, Stefania, Barabino, Silvia M.L. · 2020 · Progress in Neurobiology
Cited by 61

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Amyotrophic lateral sclerosis (ALS) is a relentless and fatal neurological disease characterized by the selective degeneration of motor neurons. No effective therapy is available for this disease. Several lines of evidence indicate that alteration of RNA metabolism, including microRNA (miRNA) processing, is a relevant pathogenetic factor and a possible therapeutic target for ALS. Here, we showed that the abundance of components in the miRNA processing machinery is altered in a SOD1-linked cellular model, suggesting consequent dysregulation of miRNA biogenesis. Indeed, high-throughput sequencing of the small RNA fraction showed that among the altered miRNAs, miR-129-5p was increased in different models of SOD1-linked ALS and in peripheral blood cells of sporadic ALS patients. We demonstrated that miR-129-5p upregulation causes the downregulation of one of its targets: the RNA-binding protein ELAVL4/HuD. ELAVL4/HuD is predominantly expressed in neurons, where it controls several key neuronal mRNAs. Overexpression of pre-miR-129-1 inhibited neurite outgrowth and differentiation via HuD silencing in vitro, while its inhibition with an antagomir rescued the phenotype. Remarkably, we showed that administration of an antisense oligonucleotide (ASO) inhibitor of miR-129-5p to an ALS animal model, SOD1 (G93A) mice, result in a significant increase in survival and improved the neuromuscular phenotype in treated mice. These results identify miR-129-5p as a therapeutic target that is amenable to ASO modulation for the treatment of ALS patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pneurobio.2020.101803

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 61

Metadata

Authors
Loffreda, A., Nizzardo, M., Arosio, A., Ruepp, M.-D., Calogero, R. A., Volinia, S., Galasso, M., Bendotti, C., Ferrarese, C., Lunetta, C., Rizzuti, M., Ronchi, A. E., Mühlemann, O., Tremolizzo, L., Corti, S., & Barabino, S. M. L.
Venue
Progress in Neurobiology
Publisher
Elsevier BV
Published
2020-07
Volume
190
Pages
101803
ISSN
0301-0082 (ISSN-L)
OpenAlex
W3018861406
Cited by
61
References
36
FWCI
2.78
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosis. https://app.cochat.ai/papers/10.1016/j.pneurobio.2020.101803
The paper
Loffreda, A., Nizzardo, M., Arosio, A., Ruepp, M.-D., Calogero, R. A., Volinia, S., Galasso, M., Bendotti, C., Ferrarese, C., Lunetta, C., Rizzuti, M., Ronchi, A. E., Mühlemann, O., Tremolizzo, L., Corti, S., & Barabino, S. M. L. (2020). miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosis. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2020.101803

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.